New paper below.
As someone who received treatment for a single spiny met at L5 last year, I am naturally interested in the subject.
"Reports on surgical and radiation treatment for low-volume metastatic recurrence have shown promising results, with definitive cure in few but a relevant delay of androgen-deprivation therapy with both treatment methods."
It's a Belgian paper, which might explain the curious phrasing in the Abstract.
First time I have seen a paper from the "Arab Journal of Urology". I doubt that any of our doctors will read it.
Arab J Urol. 2016 Jul 20;14(3):179-82. doi: 10.1016/j.aju.2016.06.004. eCollection 2016.
Oligometastatic prostate cancer: Metastases-directed therapy?
Van Poppel H1, De Meerleer G1, Joniau S1.
1Department of Urology and Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
Since the introduction of anatomical and functional imaging with multiparametric magnetic resonance imaging and choline or prostate-specific membrane antigen positron emission tomography-computed tomography, we are able to diagnose a previously unknown disease, the oligometastatic prostate cancer after local therapy. Reports on surgical and radiation treatment for low-volume metastatic recurrence have shown promising results, with definitive cure in few but a relevant delay of androgen-deprivation therapy with both treatment methods. Obviously, these results need to be validated with prospective randomised data.
(SB)RT, (stereotactic body) radiotherapy; ADT, androgen-deprivation therapy; BRFS, biochemical recurrence-free survival; CPFS, clinical progression-free survival; CSS, cancer-specific survival; LND, lymph node dissection; Lymph node dissection; Oligometastatic prostate cancer; PET, positron emission tomography; Stereotactic body radiotherapy
PMID: 27547457 DOI: 10.1016/j.aju.2016.06.004